Phaseline

Companies › Dynavax Technologies

Dynavax Technologies: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Vaccines, Infectious disease; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
rF1V-1018
Recombinant F1 antigen and V antigen fusion vaccine
–Phase 2Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia PestisJan 2027
Z-1018
Herpes Zoster vaccine
–Phase 1ShinglesJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07207408rF1V-1018Phase 2Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia PestisInfectious diseaseJan 2027
NCT06569823Z-1018Phase 1ShinglesVaccinesJun 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Cellid Guangzhou Patronus Biotech Aribio Lab Vaxcyte Inventprise

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.